NCT06626412 · ACTIVE NOT RECRUITING
Longitudinal SV2A PET and MRI in Premanifest HD
This trial is testing whether a specialized PET scan (using a tracer called 18F-SynVesT-1 that measures synaptic density) is better than standard volumetric MRI at detecting early brain changes in people who carry the Huntington's disease gene mutation but don't yet have symptoms. Participants get both scans at the start and again two years later. This is a Phase NA diagnostic imaging study — it is not testing a treatment.
Eligibility criteria
Inclusion Criteria: * Age 20-75 years inclusive. * Capacity to understand the informed consent form. * HD mutation carriers: * HTT (CAG)n ≥ 40 * HD-ISS \< 2 * CAP100 score > 70 Exclusion Criteria: * neuropsychiatric diseases (other than HD for HD mutation carriers) * major internal medical diseases * white matter lesion load on FLAIR Fazekas score 2 or higher or other relevant MRI abnormalities * history of alcohol abuse or current alcohol abuse (chronic use of more than 15 units per week) or drug abuse * contraindications for MR * pregnancy * previous participation in other research studies involving ionizing radiation with more than 1 mSv in the previous 12 months.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-05-05